Birchview Capital’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.94M | Buy |
9,000
+4,000
| +80% | +$765K | 0.91% | 29 |
|
|
2026
Q1 | $917K | Buy |
+5,000
| New | +$921K | 0.52% | 42 |
|
|
2022
Q2 | – | Sell |
-10,100
| Closed | -$2.06M | – | 63 |
|
|
2022
Q1 | $2.13M | Sell |
10,100
-2,500
| -20% | -$544K | 1.53% | 11 |
|
|
2021
Q4 | $3.02M | Hold |
12,600
| – | – | 1.95% | 10 |
|
|
2021
Q3 | $3.57M | Buy |
12,600
+500
| +4% | +$164K | 2.43% | 7 |
|
|
2021
Q2 | $4.19M | Hold |
12,100
| – | – | 2.51% | 7 |
|
|
2021
Q1 | $3.38M | Hold |
12,100
| – | – | 2.01% | 9 |
|
|
2020
Q4 | $2.96M | Buy |
12,100
+1,100
| +10% | +$284K | 1.71% | 11 |
|
|
2020
Q3 | $3.12M | Hold |
11,000
| – | – | 2.08% | 8 |
|
|
2020
Q2 | $2.94M | Hold |
11,000
| – | – | 1.78% | 9 |
|
|
2020
Q1 | $3.48M | Buy |
11,000
+6,000
| +120% | +$1.82M | 3.09% | 6 |
|
|
2019
Q4 | $1.48M | Hold |
5,000
| – | – | 1.08% | 12 |
|
|
2019
Q3 | $1.16M | Hold |
5,000
| – | – | 0.78% | 11 |
|
|
2019
Q2 | $1.17M | Buy |
5,000
+2,500
| +100% | +$577K | 0.71% | 15 |
|
|
2019
Q1 | $591K | Hold |
2,500
| – | – | 0.37% | 25 |
|
|
2018
Q4 | $752K | Buy |
2,500
+500
| +25% | +$160K | 0.71% | 18 |
|
|
2018
Q3 | $707K | Hold |
2,000
| – | – | 0.46% | 22 |
|
|
2018
Q2 | $580K | Hold |
2,000
| – | – | 0.39% | 27 |
|
|
2018
Q1 | $548K | Buy |
2,000
+1,000
| +100% | +$310K | 0.36% | 26 |
|
|
2017
Q4 | $319K | Hold |
1,000
| – | – | 0.19% | 29 |
|
|
2017
Q3 | $313K | Hold |
1,000
| – | – | 0.16% | 28 |
|
|
2017
Q2 | $271K | Hold |
1,000
| – | – | 0.14% | 29 |
|
|
2017
Q1 | $273K | Hold |
1,000
| – | – | 0.15% | 33 |
|
|
2016
Q4 | $284K | Hold |
1,000
| – | – | 0.17% | 29 |
|
|
2016
Q3 | $313K | Hold |
1,000
| – | – | 0.18% | 28 |
|
|
2016
Q2 | $242K | Hold |
1,000
| – | – | 0.18% | 29 |
|
|
2016
Q1 | $260K | Hold |
1,000
| – | – | 0.19% | 32 |
|
|
2015
Q4 | $306K | Hold |
1,000
| – | – | 0.18% | 32 |
|
|
2015
Q3 | $292K | Hold |
1,000
| – | – | 0.19% | 34 |
|
|
2015
Q2 | $404K | Sell |
1,000
-400
| -29% | -$161K | 0.21% | 30 |
|
|
2015
Q1 | $591K | Hold |
1,400
| – | – | 0.31% | 26 |
|
|
2014
Q4 | $475K | Buy |
+1,400
| New | +$453K | 0.28% | 26 |
|
Other funds holding BIIB
Birchview Capital's BIIB Position: Q2 2026 in Review
Birchview Capital increased its Biogen (BIIB) stake by 80% in Q2 2026, buying an estimated $765K and bringing the position to 9,000 shares worth $1.94M. The position accounts for 0.91% of the portfolio, ranked #29.
Birchview Capital first reported a position in BIIB in Q4 2014 and has held it in 32 quarters since. The position peaked at $4.19M in Q2 2021. 1,042 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Birchview Capital held 9,000 shares of Biogen worth $1.94M as of Q2 2026.
- Birchview Capital bought 4,000 Biogen shares in Q2 2026, an estimated $765K.
- Biogen made up 0.91% of Birchview Capital's portfolio in Q2 2026, its #29 holding.
- Birchview Capital first reported a position in Biogen in Q4 2014 and has held it in 32 quarters since.
- Birchview Capital's Biogen position peaked at $4.19M in Q2 2021.
- 1,042 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.